{"id":3169,"date":"2026-09-18T14:40:14","date_gmt":"2026-09-18T21:40:14","guid":{"rendered":"https:\/\/www.ultalabtests.com\/blog\/?p=3169"},"modified":"2026-09-20T15:55:32","modified_gmt":"2026-09-20T22:55:32","slug":"masld-fibrosis-risk-before-symptoms","status":"publish","type":"post","link":"https:\/\/www.ultalabtests.com\/blog\/liver\/masld-fibrosis-risk-before-symptoms\/","title":{"rendered":"MASLD Fibrosis Risk: Testing for Silent Liver Scarring"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">How <a href=\"https:\/\/www.ultalabtests.com\/test\/ast-test\">AST<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/alt\">ALT<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/platelet-count-edta\">platelets<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/hemoglobin-a1c-hgba1c\">A1C<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/lipid-panel-test\">lipids<\/a>, and secondary fibrosis tests work together to guide evaluation and follow-up.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>MASLD fibrosis risk can be present even when liver enzymes fall within the laboratory reference interval.<\/strong> Metabolic dysfunction-associated steatotic liver disease (MASLD) means liver fat occurs with cardiometabolic risk. Fibrosis is scar tissue. The important next question is whether scarring is likely enough to require a more specific assessment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A staged evaluation combines medical history and routine laboratory results, calculates <a href=\"https:\/\/www.ultalabtests.com\/test\/fib-4-index-liver-health-evaluation-self-calculation\">FIB-4<\/a> when appropriate, and uses elastography or an <a href=\"https:\/\/www.ultalabtests.com\/test\/enhanced-liver-fibrosis-elf-score\">Enhanced Liver Fibrosis (ELF) Score<\/a> when further assessment is needed. Ulta Lab Tests provides access to many supporting blood tests. Results require interpretation by a qualified healthcare professional and do not replace imaging, diagnosis, or individualized care.<\/p>\n\n\n\n<figure class=\"wp-block-image is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1600\" height=\"900\" src=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-fibrosis-risk-before-symptoms-hero.webp?resize=1024%2C576&amp;quality=100&amp;ssl=1\" alt=\"Clinician and patient review liver enzymes, platelets, and FIB-4 beside a liver illustration.\" class=\"wp-image-3184\" style=\"aspect-ratio:1.7777777777777777;width:1024px;height:auto\" srcset=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-fibrosis-risk-before-symptoms-hero.webp?w=1600&amp;quality=100&amp;ssl=1 1600w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-fibrosis-risk-before-symptoms-hero.webp?resize=300%2C169&amp;quality=100&amp;ssl=1 300w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-fibrosis-risk-before-symptoms-hero.webp?resize=1024%2C576&amp;quality=100&amp;ssl=1 1024w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-fibrosis-risk-before-symptoms-hero.webp?resize=768%2C432&amp;quality=100&amp;ssl=1 768w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-fibrosis-risk-before-symptoms-hero.webp?resize=1536%2C864&amp;quality=100&amp;ssl=1 1536w\" sizes=\"auto, (max-width: 1000px) 100vw, 1000px\" \/><figcaption class=\"wp-element-caption\">MASLD fibrosis assessment combines medical history, suitable laboratory results, and secondary testing when needed.<\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Key Takeaways<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Normal <a href=\"https:\/\/www.ultalabtests.com\/test\/alt\">ALT<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/ast-test\">AST<\/a> cannot exclude MASH or clinically important fibrosis.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/fib-4-index-liver-health-evaluation-self-calculation\">FIB-4<\/a> uses age, <a href=\"https:\/\/www.ultalabtests.com\/test\/ast-test\">AST<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/alt\">ALT<\/a>, and <a href=\"https:\/\/www.ultalabtests.com\/test\/platelet-count-edta\">platelets<\/a> to estimate advanced-fibrosis probability.<\/li>\n\n\n\n<li>Age, acute illness, muscle injury, and non-liver platelet disorders can change the score.<\/li>\n\n\n\n<li>An indeterminate or higher-risk result generally calls for secondary assessment.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/enhanced-liver-fibrosis-elf-score\">ELF<\/a> thresholds depend on the clinical pathway and the question being asked.<\/li>\n\n\n\n<li>Improving <a href=\"https:\/\/www.ultalabtests.com\/test\/hemoglobin-a1c-hgba1c\">A1C<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/lipid-panel-test\">lipids<\/a>, or liver enzymes does not independently prove fibrosis regression.<\/li>\n\n\n\n<li>Bleeding or new confusion requires emergency assessment, not routine testing.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">What Are MASLD, MASH, and Fibrosis?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">MASLD describes hepatic steatosis\u2014excess liver fat\u2014plus at least one defined cardiometabolic risk factor. MASH, formerly called NASH, adds liver-cell injury and inflammation. Fibrosis may occur with MASH, but inflammation and scarring are different findings. Histologic stages range from F0, no fibrosis, through F4, cirrhosis; clinically significant fibrosis generally means F2 or greater, while advanced fibrosis usually means F3\u2013F4.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">MetALD describes overlapping metabolic dysfunction and alcohol exposure within specified ranges. Alcohol and metabolic risk can contribute together. The classification thresholds are not personal safe-drinking limits. For terminology and first evaluation, read the <a href=\"https:\/\/www.ultalabtests.com\/blog\/liver\/nonalcoholic-fatty-liver-disease-masld-blood-tests\/\">introductory MASLD blood-testing guide<\/a> and the <a href=\"https:\/\/www.aasld.org\/new-masld-nomenclature\">AASLD nomenclature framework<\/a>.<\/p>\n\n\n\n<figure class=\"wp-block-image is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1280\" height=\"720\" src=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-mash-metald-differences-Large.jpeg?resize=1024%2C576&amp;quality=100&amp;ssl=1\" alt=\"Comparison of MASLD, MASH, and MetALD showing metabolic risk, inflammation, and alcohol-related overlap.\" class=\"wp-image-3189\" style=\"aspect-ratio:1.7777777777777777;width:1024px;height:auto\" srcset=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-mash-metald-differences-Large.jpeg?w=1280&amp;quality=100&amp;ssl=1 1280w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-mash-metald-differences-Large.jpeg?resize=300%2C169&amp;quality=100&amp;ssl=1 300w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-mash-metald-differences-Large.jpeg?resize=1024%2C576&amp;quality=100&amp;ssl=1 1024w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-mash-metald-differences-Large.jpeg?resize=768%2C432&amp;quality=100&amp;ssl=1 768w\" sizes=\"auto, (max-width: 1000px) 100vw, 1000px\" \/><figcaption class=\"wp-element-caption\">MASLD, MASH, and MetALD describe related but distinct clinical categories; fibrosis is a separate scarring assessment.<\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Why Assess MASLD Fibrosis Risk Before Symptoms Appear?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Symptoms and enzyme levels do not reliably reveal the amount of scar tissue.<\/strong> A person can feel well while fibrosis develops. Conversely, fatigue or abdominal discomfort can have many explanations and cannot establish liver disease.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.ultalabtests.com\/test\/alt\">ALT<\/a> (<a href=\"https:\/\/www.ultalabtests.com\/test\/alt\">alanine aminotransferase<\/a>) and <a href=\"https:\/\/www.ultalabtests.com\/test\/ast-test\">AST<\/a> (<a href=\"https:\/\/www.ultalabtests.com\/test\/ast-test\">aspartate aminotransferase<\/a>) mainly provide information about cell injury. They do not directly measure liver fat, inflammation under a microscope, or scar tissue. Fibrosis assessment matters because stage helps predict liver-related complications and informs follow-up. Cardiovascular, diabetes, and kidney risks also need attention. These distinctions underpin the <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10735173\/\">AASLD assessment guidance<\/a>.<\/p>\n\n\n\n<figure class=\"wp-block-image is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1280\" height=\"720\" src=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/normal-alt-ast-masld-fibrosis-risk-Large.jpeg?resize=1024%2C576&amp;quality=100&amp;ssl=1\" alt=\"Illustration showing that normal ALT and AST may coexist with liver fibrosis.\" class=\"wp-image-3193\" style=\"aspect-ratio:1.7777777777777777;width:1024px;height:auto\" srcset=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/normal-alt-ast-masld-fibrosis-risk-Large.jpeg?w=1280&amp;quality=100&amp;ssl=1 1280w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/normal-alt-ast-masld-fibrosis-risk-Large.jpeg?resize=300%2C169&amp;quality=100&amp;ssl=1 300w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/normal-alt-ast-masld-fibrosis-risk-Large.jpeg?resize=1024%2C576&amp;quality=100&amp;ssl=1 1024w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/normal-alt-ast-masld-fibrosis-risk-Large.jpeg?resize=768%2C432&amp;quality=100&amp;ssl=1 768w\" sizes=\"auto, (max-width: 1000px) 100vw, 1000px\" \/><figcaption class=\"wp-element-caption\">Normal <a href=\"https:\/\/www.ultalabtests.com\/test\/alt\">ALT<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/ast-test\">AST<\/a> do not reliably exclude MASH or clinically important liver scarring.<\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">When Should You Discuss Fibrosis Testing?<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Finding<\/th><th>Why it matters<\/th><th>Useful next information<\/th><\/tr><\/thead><tbody><tr><td>Type 2 diabetes; prediabetes with additional metabolic risks<\/td><td>Higher-risk setting for metabolic liver disease<\/td><td>Current liver chemistry, <a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC with platelets<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/hemoglobin-a1c-hgba1c\">A1C<\/a>, and an appropriate <a href=\"https:\/\/www.ultalabtests.com\/test\/fib-4-index-liver-health-evaluation-self-calculation\">FIB-4<\/a> calculation<\/td><\/tr><tr><td>Obesity or abdominal adiposity with metabolic complications<\/td><td>Risk increases as cardiometabolic factors cluster<\/td><td>Blood pressure, <a href=\"https:\/\/www.ultalabtests.com\/test\/glucose\">glucose<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/lipid-panel-test\">lipid panel<\/a>, history, and selected fibrosis assessment<\/td><\/tr><tr><td>Liver fat reported on imaging<\/td><td>Steatosis does not establish fibrosis stage<\/td><td>Clinical review and fibrosis risk stratification<\/td><\/tr><tr><td>Persistent <a href=\"https:\/\/www.ultalabtests.com\/test\/alt\">ALT<\/a> or <a href=\"https:\/\/www.ultalabtests.com\/test\/ast-test\">AST<\/a> elevation<\/td><td>Ongoing injury may have a competing cause<\/td><td>Exposure review and targeted blood tests or imaging<\/td><\/tr><tr><td>Falling <a href=\"https:\/\/www.ultalabtests.com\/test\/platelet-count-edta\">platelets<\/a> or family history of MASLD-related cirrhosis<\/td><td>May increase concern but is not diagnostic<\/td><td>Repeat comparable results and timely clinical assessment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">These are risk-based discussions, not a recommendation for population-wide testing or a broad panel for every reader. People with suspected cirrhosis, significant symptoms, or rapidly changing results may need direct specialist assessment.<\/p>\n\n\n\n<figure class=\"wp-block-image is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1280\" height=\"960\" src=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-who-needs-fibrosis-risk-assessment-Large.jpeg?resize=1024%2C768&amp;quality=100&amp;ssl=1\" alt=\"Risk factors that may prompt MASLD fibrosis assessment, including diabetes, metabolic risk, and imaging findings.\" class=\"wp-image-3192\" style=\"aspect-ratio:1.3333333333333333;width:1024px;height:auto\" srcset=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-who-needs-fibrosis-risk-assessment-Large.jpeg?w=1280&amp;quality=100&amp;ssl=1 1280w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-who-needs-fibrosis-risk-assessment-Large.jpeg?resize=300%2C225&amp;quality=100&amp;ssl=1 300w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-who-needs-fibrosis-risk-assessment-Large.jpeg?resize=1024%2C768&amp;quality=100&amp;ssl=1 1024w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-who-needs-fibrosis-risk-assessment-Large.jpeg?resize=768%2C576&amp;quality=100&amp;ssl=1 768w\" sizes=\"auto, (max-width: 1000px) 100vw, 1000px\" \/><figcaption class=\"wp-element-caption\">Risk factors guide an individualized discussion; this is not a universal screening checklist.<\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">A Staged Fibrosis Assessment Pathway<\/h2>\n\n\n\n<figure class=\"wp-block-image is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1280\" height=\"720\" src=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-fibrosis-testing-pathway-Large.jpeg?resize=1024%2C576&amp;quality=100&amp;ssl=1\" alt=\"Staged MASLD pathway from clinical review and baseline testing to FIB-4 and secondary fibrosis assessment.\" class=\"wp-image-3187\" style=\"aspect-ratio:1.7777777777777777;width:1024px;height:auto\" srcset=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-fibrosis-testing-pathway-Large.jpeg?w=1280&amp;quality=100&amp;ssl=1 1280w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-fibrosis-testing-pathway-Large.jpeg?resize=300%2C169&amp;quality=100&amp;ssl=1 300w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-fibrosis-testing-pathway-Large.jpeg?resize=1024%2C576&amp;quality=100&amp;ssl=1 1024w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-fibrosis-testing-pathway-Large.jpeg?resize=768%2C432&amp;quality=100&amp;ssl=1 768w\" sizes=\"auto, (max-width: 1000px) 100vw, 1000px\" \/><figcaption class=\"wp-element-caption\">A staged pathway uses suitable <a href=\"https:\/\/www.ultalabtests.com\/test\/fib-4-index-liver-health-evaluation-self-calculation\">FIB-4 inputs<\/a>, then secondary assessment or referral when indicated.<\/figcaption><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\">1. Assemble suitable baseline results<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-cmp\">Comprehensive Metabolic Panel (CMP)<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC with Differential and Platelets<\/a> commonly supply liver chemistry and the platelet input. <a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a> means <a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">complete blood count<\/a>. <a href=\"https:\/\/www.ultalabtests.com\/test\/hemoglobin-a1c-hgba1c\">Hemoglobin A1C<\/a> reflects longer-term <a href=\"https:\/\/www.ultalabtests.com\/test\/glucose\">glucose<\/a> exposure, while a <a href=\"https:\/\/www.ultalabtests.com\/test\/lipid-panel-test\">lipid panel<\/a> describes cholesterol and triglyceride-related risk. Use clinically comparable <a href=\"https:\/\/www.ultalabtests.com\/test\/ast-test\">AST<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/alt\">ALT<\/a>, and platelet results, preferably from the same collection. Review recent illness, strenuous exercise, alcohol, supplements, and prescribed medicines before calculating.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">2. Interpret <a href=\"https:\/\/www.ultalabtests.com\/test\/fib-4-index-liver-health-evaluation-self-calculation\">FIB-4<\/a> using the appropriate age group<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.ultalabtests.com\/test\/fib-4-index-liver-health-evaluation-self-calculation\">FIB-4<\/a> = (age \u00d7 <a href=\"https:\/\/www.ultalabtests.com\/test\/ast-test\">AST<\/a>) \u00f7 (<a href=\"https:\/\/www.ultalabtests.com\/test\/platelet-count-edta\">platelets<\/a> \u00d7 \u221a<a href=\"https:\/\/www.ultalabtests.com\/test\/alt\">ALT<\/a>). Age is in years, enzymes in U\/L, and <a href=\"https:\/\/www.ultalabtests.com\/test\/platelet-count-edta\">platelets<\/a> in \u00d710<sup>9<\/sup>\/L. The <a href=\"https:\/\/www.ultalabtests.com\/blog\/liver\/fib-4-index-explained-how-to-calculate-your-fib-4-score-for-liver-health-and-fibrosis-risk\/\">FIB-4 calculation guide<\/a> explains units and worked examples.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Age<\/th><th>Lower probability<\/th><th>Secondary assessment<\/th><th>Higher concern<\/th><\/tr><\/thead><tbody><tr><td>35\u201364 years<\/td><td>Below 1.3<\/td><td>1.3\u20132.67<\/td><td>Above 2.67<\/td><\/tr><tr><td>65 years or older<\/td><td>Below 2.0<\/td><td>2.0\u20132.67<\/td><td>Above 2.67<\/td><\/tr><tr><td>Younger than 35<\/td><td colspan=\"3\">Accuracy is limited. Substantial metabolic risk or persistent liver abnormalities may justify another assessment despite a low score.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The age bands above follow the <a href=\"https:\/\/news.gastro.org\/issues\/2026\/march\/aga-updates-masld-care-pathway\/\">2026 AGA pathway summary<\/a>; AASLD's earlier guidance describes the older group as over 65. Use the clinician's selected pathway at that boundary. Do not use <a href=\"https:\/\/www.ultalabtests.com\/test\/fib-4-index-liver-health-evaluation-self-calculation\">FIB-4<\/a> to assess chronic fibrosis during acute illness. A low result reduces the probability of advanced fibrosis; it does not exclude all fibrosis, MASH, or another liver disorder.<\/p>\n\n\n\n<figure class=\"wp-block-image is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1280\" height=\"960\" src=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/fib-4-score-inputs-age-thresholds-Large.jpeg?resize=1024%2C768&amp;quality=100&amp;ssl=1\" alt=\"FIB-4 inputs and age-adjusted thresholds for adults aged 35\u201364 and adults aged 65 or older.\" class=\"wp-image-3186\" style=\"aspect-ratio:1.3333333333333333;width:1024px;height:auto\" srcset=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/fib-4-score-inputs-age-thresholds-Large.jpeg?w=1280&amp;quality=100&amp;ssl=1 1280w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/fib-4-score-inputs-age-thresholds-Large.jpeg?resize=300%2C225&amp;quality=100&amp;ssl=1 300w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/fib-4-score-inputs-age-thresholds-Large.jpeg?resize=1024%2C768&amp;quality=100&amp;ssl=1 1024w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/fib-4-score-inputs-age-thresholds-Large.jpeg?resize=768%2C576&amp;quality=100&amp;ssl=1 768w\" sizes=\"auto, (max-width: 1000px) 100vw, 1000px\" \/><figcaption class=\"wp-element-caption\">The displayed age bands follow the AGA pathway summary. <a href=\"https:\/\/www.ultalabtests.com\/test\/fib-4-index-liver-health-evaluation-self-calculation\">FIB-4<\/a> has limited accuracy below age 35 and should not assess chronic fibrosis during acute illness.<\/figcaption><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\">3. Use secondary testing when indicated<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Secondary tests refine risk; they do not simply repeat the information in liver enzymes.<\/strong> Vibration-controlled transient elastography (VCTE), often called FibroScan, estimates liver stiffness. <a href=\"https:\/\/www.ultalabtests.com\/test\/enhanced-liver-fibrosis-elf-score\">ELF<\/a> is a blood-based score related to extracellular-matrix turnover. Magnetic resonance elastography may help with selected or discordant findings.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Assessment<\/th><th>Practical interpretation<\/th><th>Limitations<\/th><\/tr><\/thead><tbody><tr><td>VCTE\/FibroScan<\/td><td>Below 8 kPa generally supports lower risk; 8 kPa or higher prompts further stratification or referral in the AGA pathway.<\/td><td>Food intake, inflammation, congestion, body habitus, and measurement quality affect stiffness. A value of 8 kPa is not a diagnosis of advanced fibrosis.<\/td><\/tr><tr><td><a href=\"https:\/\/www.ultalabtests.com\/test\/enhanced-liver-fibrosis-elf-score\">Enhanced Liver Fibrosis (ELF) Score<\/a><\/td><td>Provides additional fibrosis-risk information when appropriate, including when elastography is unavailable.<\/td><td>A score must be interpreted using the intended pathway and population.<\/td><\/tr><tr><td>Magnetic resonance elastography<\/td><td>May clarify risk when initial tests disagree or concern remains.<\/td><td>Access, cost, and technical factors affect suitability.<\/td><\/tr><tr><td>Liver biopsy<\/td><td>Examines fat, inflammation, cell injury, and fibrosis in tissue.<\/td><td>Invasive and subject to sampling variation; not required for every patient.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">FibroScan, magnetic resonance elastography, and biopsy are procedures arranged through clinical services. Routine ultrasound may identify steatosis but cannot reliably stage fibrosis or prove MASH. The <a href=\"https:\/\/www.niddk.nih.gov\/health-information\/liver-disease\/nafld-nash\/diagnosis\">NIDDK diagnosis guide<\/a> explains these distinctions.<\/p>\n\n\n\n<figure class=\"wp-block-image is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1280\" height=\"960\" src=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-secondary-fibrosis-tests-comparison-Large.jpeg?resize=1024%2C768&amp;quality=100&amp;ssl=1\" alt=\"Comparison of ELF, transient elastography, magnetic resonance elastography, and liver biopsy.\" class=\"wp-image-3191\" style=\"aspect-ratio:1.3333333333333333;width:1024px;height:auto\" srcset=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-secondary-fibrosis-tests-comparison-Large.jpeg?w=1280&amp;quality=100&amp;ssl=1 1280w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-secondary-fibrosis-tests-comparison-Large.jpeg?resize=300%2C225&amp;quality=100&amp;ssl=1 300w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-secondary-fibrosis-tests-comparison-Large.jpeg?resize=1024%2C768&amp;quality=100&amp;ssl=1 1024w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-secondary-fibrosis-tests-comparison-Large.jpeg?resize=768%2C576&amp;quality=100&amp;ssl=1 768w\" sizes=\"auto, (max-width: 1000px) 100vw, 1000px\" \/><figcaption class=\"wp-element-caption\"><a href=\"https:\/\/www.ultalabtests.com\/test\/enhanced-liver-fibrosis-elf-score\">ELF<\/a>, elastography, and biopsy measure different features. Their thresholds and limitations are not interchangeable.<\/figcaption><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\">Why do <a href=\"https:\/\/www.ultalabtests.com\/test\/enhanced-liver-fibrosis-elf-score\">ELF<\/a> thresholds differ?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The <a href=\"https:\/\/news.gastro.org\/issues\/2026\/march\/aga-updates-masld-care-pathway\/\">2026 AGA pathway summary<\/a> uses an <a href=\"https:\/\/www.ultalabtests.com\/test\/enhanced-liver-fibrosis-elf-score\">ELF<\/a> threshold of 9.2 for identifying clinically significant fibrosis when elastography is unavailable. The <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10735173\/\">AASLD guidance<\/a> lists 9.8 in its advanced-fibrosis assessment table and discusses 11.3 for predicting liver-related events in people with suspected or confirmed advanced disease. Different endpoints and clinical settings explain why these values are not interchangeable. An <a href=\"https:\/\/www.ultalabtests.com\/test\/enhanced-liver-fibrosis-elf-score\">ELF<\/a> result between 9.2 and 9.8 should not automatically be dismissed as reassuring.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">4. Investigate alternative causes selectively<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Metabolic risk does not exclude viral hepatitis, <a href=\"https:\/\/www.ultalabtests.com\/test\/iron-and-total-iron-binding-capacity-test\">iron<\/a> overload, autoimmune disease, medication injury, or alcohol-related disease. A clinician may select a hepatitis B triple panel (<a href=\"https:\/\/www.ultalabtests.com\/test\/hepatitis-b-surface-antigen-test-with-reflex-to-confirmation\">HBsAg<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/hepatitis-b-surface-antibody-quantitative\">anti-HBs<\/a>, and <a href=\"https:\/\/www.ultalabtests.com\/test\/hepatitis-b-core-antibody-total\">total anti-HBc<\/a>), <a href=\"https:\/\/www.ultalabtests.com\/test\/hepatitis-c-antibody-test-with-reflex-to-rna-quantitative-pcr\">Hepatitis C Antibody with Reflex to HCV RNA<\/a>, or <a href=\"https:\/\/www.ultalabtests.com\/test\/ferritin-test\">ferritin<\/a> with <a href=\"https:\/\/www.ultalabtests.com\/test\/iron-and-total-iron-binding-capacity-test\">iron and TIBC<\/a> (<a href=\"https:\/\/www.ultalabtests.com\/test\/iron-and-total-iron-binding-capacity-test\">total iron-binding capacity<\/a>). Persistent unexplained findings may justify <a href=\"https:\/\/www.ultalabtests.com\/test\/ana-screen-ifa-with-reflex-to-titer-and-pattern\">ANA<\/a> (<a href=\"https:\/\/www.ultalabtests.com\/test\/ana-screen-ifa-with-reflex-to-titer-and-pattern\">antinuclear antibodies<\/a>), <a href=\"https:\/\/www.ultalabtests.com\/test\/actin-smooth-muscle-igg-antibody-test\">smooth-muscle antibody<\/a>, and <a href=\"https:\/\/www.ultalabtests.com\/test\/igg-test\">IgG<\/a> (<a href=\"https:\/\/www.ultalabtests.com\/test\/igg-test\">immunoglobulin G<\/a>). Positive autoimmune markers alone do not establish autoimmune hepatitis. <a href=\"https:\/\/www.ultalabtests.com\/test\/creatine-kinase-total-test\">CK<\/a> (<a href=\"https:\/\/www.ultalabtests.com\/test\/creatine-kinase-total-test\">creatine kinase<\/a>) may clarify an <a href=\"https:\/\/www.ultalabtests.com\/test\/ast-test\">AST<\/a> elevation associated with muscle injury.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Related Lab Tests and Biomarkers<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Test or panel<\/th><th>Role and possible findings<\/th><th>Important limitation<\/th><\/tr><\/thead><tbody><tr><td><a href=\"https:\/\/www.ultalabtests.com\/test\/fib-4-index-liver-health-evaluation-self-calculation\">FIB-4 Index Liver Health Evaluation (Self Calculation)<\/a><\/td><td>Laboratory inputs used with age to estimate advanced-fibrosis probability<\/td><td>A calculation, not a tissue measurement or cirrhosis diagnosis<\/td><\/tr><tr><td><a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-cmp\">Comprehensive Metabolic Panel (CMP)<\/a><\/td><td>Liver chemistry, <a href=\"https:\/\/www.ultalabtests.com\/test\/glucose\">glucose<\/a>, and kidney context; abnormal patterns guide evaluation<\/td><td>Does not measure liver fat or scarring directly<\/td><\/tr><tr><td><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC with Differential and Platelets<\/a><\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/platelet-count-edta\">Platelets<\/a> for the calculation; blood-cell findings may reveal other problems<\/td><td>Low <a href=\"https:\/\/www.ultalabtests.com\/test\/platelet-count-edta\">platelets<\/a> have many non-liver causes<\/td><\/tr><tr><td><a href=\"https:\/\/www.ultalabtests.com\/test\/hemoglobin-a1c-hgba1c\">Hemoglobin A1C<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/lipid-panel-test\">lipid panel<\/a><\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/glucose\">Glucose<\/a> exposure and lipid-related cardiovascular risk<\/td><td>Improvement does not prove fibrosis regression<\/td><\/tr><tr><td><a href=\"https:\/\/www.ultalabtests.com\/test\/apolipoprotein-b-test\">Apolipoprotein B<\/a><\/td><td>Selected cardiovascular assessment when particle-related risk needs clarification<\/td><td>Not a fibrosis marker or universal requirement<\/td><\/tr><tr><td><a href=\"https:\/\/www.ultalabtests.com\/test\/ferritin-iron-and-total-iron-binding-capacity-panel\">Ferritin, Iron and TIBC Panel<\/a><\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/iron-and-total-iron-binding-capacity-test\">Iron<\/a> storage and availability; saturation helps investigate overload<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/ferritin-test\">Ferritin<\/a> also rises with inflammation and liver injury<\/td><\/tr><tr><td><a href=\"https:\/\/www.ultalabtests.com\/test\/enhanced-liver-fibrosis-elf-score\">Enhanced Liver Fibrosis (ELF) Score<\/a><\/td><td>Secondary fibrosis-risk assessment<\/td><td>Threshold and intended use matter<\/td><\/tr><tr><td><a href=\"https:\/\/www.ultalabtests.com\/test\/albumin-random-urine-test-with-creatinine\">Albumin Random Urine with Creatinine<\/a><\/td><td>Kidney-injury assessment when diabetes or another indication warrants it<\/td><td>Urine findings can be transient and do not stage liver disease<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<figure class=\"wp-block-image is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1280\" height=\"960\" src=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-related-lab-test-clusters-Large.jpeg?resize=1024%2C768&amp;quality=100&amp;ssl=1\" alt=\"Laboratory groups for liver chemistry, metabolic health, fibrosis risk, and selected alternative causes.\" class=\"wp-image-3190\" style=\"aspect-ratio:1.3333333333333333;width:1024px;height:auto\" srcset=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-related-lab-test-clusters-Large.jpeg?w=1280&amp;quality=100&amp;ssl=1 1280w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-related-lab-test-clusters-Large.jpeg?resize=300%2C225&amp;quality=100&amp;ssl=1 300w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-related-lab-test-clusters-Large.jpeg?resize=1024%2C768&amp;quality=100&amp;ssl=1 1024w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-related-lab-test-clusters-Large.jpeg?resize=768%2C576&amp;quality=100&amp;ssl=1 768w\" sizes=\"auto, (max-width: 1000px) 100vw, 1000px\" \/><figcaption class=\"wp-element-caption\">Select laboratory groups to answer specific questions; not every patient needs every test shown.<\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">How Can Similar Laboratory Results Mean Different Things?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The following examples are fictional teaching cases, not diagnostic rules. Enzymes are in U\/L, <a href=\"https:\/\/www.ultalabtests.com\/test\/platelet-count-edta\">platelets<\/a> in \u00d710<sup>9<\/sup>\/L, <a href=\"https:\/\/www.ultalabtests.com\/test\/ferritin-test\">ferritin<\/a> in ng\/mL, and <a href=\"https:\/\/www.ultalabtests.com\/test\/iron-and-total-iron-binding-capacity-test\">transferrin saturation<\/a> in percent. Laboratory reference intervals vary.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Pattern<\/th><th>What it illustrates<\/th><th>Discussion to have<\/th><\/tr><\/thead><tbody><tr><td>Age 60; <a href=\"https:\/\/www.ultalabtests.com\/test\/ast-test\">AST<\/a> 30; <a href=\"https:\/\/www.ultalabtests.com\/test\/alt\">ALT<\/a> 25; <a href=\"https:\/\/www.ultalabtests.com\/test\/platelet-count-edta\">platelets<\/a> 120; <a href=\"https:\/\/www.ultalabtests.com\/test\/fib-4-index-liver-health-evaluation-self-calculation\">FIB-4<\/a> 3.00<\/td><td>Enzymes may be within the reported interval while fibrosis risk is elevated.<\/td><td>Arrange secondary assessment and investigate the low <a href=\"https:\/\/www.ultalabtests.com\/test\/platelet-count-edta\">platelet count<\/a>.<\/td><\/tr><tr><td>Age 50; <a href=\"https:\/\/www.ultalabtests.com\/test\/ast-test\">AST<\/a> 60; <a href=\"https:\/\/www.ultalabtests.com\/test\/alt\">ALT<\/a> 90; <a href=\"https:\/\/www.ultalabtests.com\/test\/platelet-count-edta\">platelets<\/a> 350; <a href=\"https:\/\/www.ultalabtests.com\/test\/fib-4-index-liver-health-evaluation-self-calculation\">FIB-4<\/a> 0.90; enzymes persistently elevated for over six months<\/td><td>A low fibrosis-risk score does not explain persistent injury.<\/td><td>Evaluate alternative or coexisting causes.<\/td><\/tr><tr><td><a href=\"https:\/\/www.ultalabtests.com\/test\/ferritin-test\">Ferritin<\/a> 450; <a href=\"https:\/\/www.ultalabtests.com\/test\/iron-and-total-iron-binding-capacity-test\">transferrin saturation<\/a> 24%<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/ferritin-test\">Ferritin<\/a> alone cannot establish <a href=\"https:\/\/www.ultalabtests.com\/test\/iron-and-total-iron-binding-capacity-test\">iron<\/a> overload.<\/td><td>Consider inflammation, liver injury, alcohol, and other explanations.<\/td><\/tr><tr><td><a href=\"https:\/\/www.ultalabtests.com\/test\/ferritin-test\">Ferritin<\/a> 450; <a href=\"https:\/\/www.ultalabtests.com\/test\/iron-and-total-iron-binding-capacity-test\">transferrin saturation<\/a> 68%<\/td><td>Persistently high saturation increases concern about <a href=\"https:\/\/www.ultalabtests.com\/test\/iron-and-total-iron-binding-capacity-test\">iron<\/a> loading.<\/td><td>Discuss focused iron-overload evaluation; do not self-diagnose.<\/td><\/tr><tr><td><a href=\"https:\/\/www.ultalabtests.com\/test\/hemoglobin-a1c-hgba1c\">A1C<\/a>, weight, and <a href=\"https:\/\/www.ultalabtests.com\/test\/alt\">ALT<\/a> improve, but an appropriately interpreted fibrosis assessment remains concerning<\/td><td>Metabolic improvement and residual liver risk can coexist.<\/td><td>Complete the planned fibrosis follow-up.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">How Should Follow-Up Results Be Understood?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Follow the metabolic pattern and the fibrosis question separately, then interpret them together.<\/strong> <a href=\"https:\/\/www.ultalabtests.com\/test\/hemoglobin-a1c-hgba1c\">A1C<\/a> describes <a href=\"https:\/\/www.ultalabtests.com\/test\/glucose\">glucose<\/a> exposure; <a href=\"https:\/\/www.ultalabtests.com\/test\/lipid-panel-test\">lipid results<\/a> describe cardiovascular risk; enzymes describe injury signals; and fibrosis assessments address scarring probability. None is a substitute for the others.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.ultalabtests.com\/test\/fib-4-index-liver-health-evaluation-self-calculation\">FIB-4<\/a> changes can reflect aging, enzyme fluctuations, or a platelet change unrelated to the liver. Improvement in the score may be encouraging but does not, by itself, prove scar tissue has regressed. Likewise, rising scores do not automatically prove progression. Comparable collection conditions and secondary testing help resolve uncertainty. See the <a href=\"https:\/\/www.ultalabtests.com\/blog\/liver\/liver-health-metabolic-dashboard-lab-tests\/\">whole-body liver laboratory dashboard<\/a> for the broader connections.<\/p>\n\n\n\n<figure class=\"wp-block-image is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1280\" height=\"720\" src=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-lab-testing-can-and-cannot-show-Large.jpeg?resize=1024%2C576&amp;quality=100&amp;ssl=1\" alt=\"Comparison of what liver blood tests can suggest and what they cannot establish alone.\" class=\"wp-image-3188\" style=\"aspect-ratio:1.7777777777777777;width:1024px;height:auto\" srcset=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-lab-testing-can-and-cannot-show-Large.jpeg?w=1280&amp;quality=100&amp;ssl=1 1280w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-lab-testing-can-and-cannot-show-Large.jpeg?resize=300%2C169&amp;quality=100&amp;ssl=1 300w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-lab-testing-can-and-cannot-show-Large.jpeg?resize=1024%2C576&amp;quality=100&amp;ssl=1 1024w, https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-lab-testing-can-and-cannot-show-Large.jpeg?resize=768%2C432&amp;quality=100&amp;ssl=1 768w\" sizes=\"auto, (max-width: 1000px) 100vw, 1000px\" \/><figcaption class=\"wp-element-caption\">Better <a href=\"https:\/\/www.ultalabtests.com\/test\/hemoglobin-a1c-hgba1c\">A1C<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/lipid-panel-test\">lipids<\/a>, or liver enzymes does not independently demonstrate that scar tissue has regressed.<\/figcaption><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\">How often is reassessment appropriate?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">AASLD commonly recommends repeating <a href=\"https:\/\/www.ultalabtests.com\/test\/fib-4-index-liver-health-evaluation-self-calculation\">FIB-4<\/a> every one to two years for people with prediabetes, type 2 diabetes, or multiple metabolic risks, and every two to three years for selected people without prediabetes or diabetes and with fewer risks. The AGA pathway uses one- to two-year reassessment for low-risk patients. A clinician chooses the interval. An indeterminate or higher-risk result generally requires secondary evaluation rather than waiting for the next routine check.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">What does treatment progress mean?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Smaller sustained weight reductions may improve liver fat; AASLD describes about 3%\u20135% for steatosis improvement and generally greater than 10% for improvement in steatohepatitis and fibrosis. These are population findings, not individual guarantees. Physical activity and management of <a href=\"https:\/\/www.ultalabtests.com\/test\/glucose\">glucose<\/a>, blood pressure, and cardiovascular risk remain relevant.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">FDA has approved resmetirom and Wegovy (semaglutide) injection for selected adults with noncirrhotic MASH and moderate-to-advanced fibrosis, under accelerated approval. A high enzyme value or <a href=\"https:\/\/www.ultalabtests.com\/test\/fib-4-index-liver-health-evaluation-self-calculation\">FIB-4<\/a> alone does not establish eligibility. Disease staging, current labeling, interactions, and contraindications require clinician review. See the FDA announcements for <a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease\">resmetirom<\/a> and <a href=\"https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash\">Wegovy for MASH<\/a>. Do not start, stop, or change medication based on this article.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Preparing for Testing and Discussing Results<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Check the instructions for the exact ordered tests. The <a href=\"https:\/\/www.ultalabtests.com\/test\/fib-4-index-liver-health-evaluation-self-calculation\">FIB-4<\/a> calculation itself does not require fasting, but accompanying <a href=\"https:\/\/www.ultalabtests.com\/test\/glucose\">glucose<\/a> or <a href=\"https:\/\/www.ultalabtests.com\/test\/lipid-panel-test\">lipid testing<\/a> may have specific instructions. Bring identification and collection paperwork as directed. Report recent illness, exercise, alcohol, and medicines; do not stop a prescription without instructions from the prescriber.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Are these results suitable for calculating <a href=\"https:\/\/www.ultalabtests.com\/test\/fib-4-index-liver-health-evaluation-self-calculation\">FIB-4<\/a> now?<\/li>\n\n\n\n<li>Does my age or another condition change interpretation?<\/li>\n\n\n\n<li>Do I need <a href=\"https:\/\/www.ultalabtests.com\/test\/enhanced-liver-fibrosis-elf-score\">ELF<\/a>, elastography, or specialist assessment?<\/li>\n\n\n\n<li>Could another cause explain the enzyme or platelet pattern?<\/li>\n\n\n\n<li>Which findings should improve, and what will measure fibrosis risk?<\/li>\n\n\n\n<li>What is my follow-up interval and what should trigger earlier care?<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">When Should You Seek Urgent Care?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Vomiting blood, black tarry stools with weakness or fainting, or new confusion or marked drowsiness can be emergencies: seek emergency care immediately. New jaundice, rapidly increasing abdominal swelling, or severe upper-abdominal pain with fever or vomiting requires urgent assessment. Do not delay care to order routine blood tests.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">How Ulta Lab Tests Helps<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ulta Lab Tests lets patients explore many laboratory tests online where available, review listed prices, and receive results through a secure portal. Testing uses established laboratory services, including Quest Diagnostics where applicable. Insurance is not required, and eligible HSA\/FSA payment may be available. Choose tests around a defined clinical question and review results with a qualified healthcare professional.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Can normal <a href=\"https:\/\/www.ultalabtests.com\/test\/alt\">ALT<\/a> rule out liver fibrosis?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No. <a href=\"https:\/\/www.ultalabtests.com\/test\/alt\">ALT<\/a> can be within the laboratory reference interval despite clinically important scarring. Interpretation also considers metabolic risk, imaging, <a href=\"https:\/\/www.ultalabtests.com\/test\/platelet-count-edta\">platelets<\/a>, and an appropriate fibrosis assessment. A normal enzyme result is information about that measurement, not proof that liver fat, MASH, or fibrosis is absent.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">What is the first blood test for MASLD fibrosis risk?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Many pathways begin with <a href=\"https:\/\/www.ultalabtests.com\/test\/fib-4-index-liver-health-evaluation-self-calculation\">FIB-4<\/a>, a calculation using age, <a href=\"https:\/\/www.ultalabtests.com\/test\/ast-test\">AST<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/alt\">ALT<\/a>, and <a href=\"https:\/\/www.ultalabtests.com\/test\/platelet-count-edta\">platelets<\/a>. The laboratory inputs may already be available from suitable recent testing. It estimates advanced-fibrosis probability and helps decide whether another assessment is appropriate; it is not a stand-alone diagnosis or a direct measurement of scarring.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Does a high <a href=\"https:\/\/www.ultalabtests.com\/test\/fib-4-index-liver-health-evaluation-self-calculation\">FIB-4<\/a> mean cirrhosis?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No. A high score raises concern but can also reflect age, muscle-related <a href=\"https:\/\/www.ultalabtests.com\/test\/ast-test\">AST<\/a> elevation, acute illness, or low <a href=\"https:\/\/www.ultalabtests.com\/test\/platelet-count-edta\">platelets<\/a> from another condition. A healthcare professional reviews the inputs and may arrange elastography, <a href=\"https:\/\/www.ultalabtests.com\/test\/enhanced-liver-fibrosis-elf-score\">ELF<\/a>, or specialist evaluation. Do not translate the numerical score directly into a fibrosis stage.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Is <a href=\"https:\/\/www.ultalabtests.com\/test\/enhanced-liver-fibrosis-elf-score\">ELF<\/a> the same as FibroScan?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No. <a href=\"https:\/\/www.ultalabtests.com\/test\/enhanced-liver-fibrosis-elf-score\">ELF<\/a> is a blood-based composite score related to fibrosis-associated matrix turnover. FibroScan is an imaging-based procedure that estimates liver stiffness and can also assess steatosis through a separate measurement. They supply different information and have different limitations; the best next assessment depends on clinical context and availability.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Why might one clinician use <a href=\"https:\/\/www.ultalabtests.com\/test\/enhanced-liver-fibrosis-elf-score\">ELF<\/a> 9.2 and another 9.8?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Thresholds depend on the pathway, population, and clinical endpoint. The AGA summary uses 9.2 for clinically significant fibrosis detection, whereas AASLD lists 9.8 for advanced-fibrosis assessment. Neither number should be treated as a universal diagnostic boundary. Ask which framework applies to the result and what follow-up it supports.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Does lower <a href=\"https:\/\/www.ultalabtests.com\/test\/hemoglobin-a1c-hgba1c\">A1C<\/a> mean my liver has recovered?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Lower <a href=\"https:\/\/www.ultalabtests.com\/test\/hemoglobin-a1c-hgba1c\">A1C<\/a> can indicate improved <a href=\"https:\/\/www.ultalabtests.com\/test\/glucose\">glucose<\/a> exposure, which is valuable for metabolic health. It does not measure liver scarring. Enzymes, <a href=\"https:\/\/www.ultalabtests.com\/test\/platelet-count-edta\">platelets<\/a>, clinical findings, and fibrosis assessments may follow different timelines. Continue the agreed follow-up plan even when <a href=\"https:\/\/www.ultalabtests.com\/test\/glucose\">glucose<\/a> control, weight, or other metabolic results improve substantially.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Do I need a liver biopsy?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Not everyone does. Clinicians often use noninvasive assessments first. Biopsy may help when results conflict, another diagnosis remains possible, or greater certainty would change care. The decision weighs likely benefit against procedural risks and sampling limitations; a high <a href=\"https:\/\/www.ultalabtests.com\/test\/fib-4-index-liver-health-evaluation-self-calculation\">FIB-4<\/a> alone does not automatically require biopsy.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Can I order the blood tests myself?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Many supporting tests can be ordered online through Ulta Lab Tests where available. Ordering access does not replace clinical interpretation or arrange imaging automatically. Review appropriate tests with a healthcare professional, especially when a score is elevated, symptoms are present, or you already have known liver disease.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Putting MASLD Fibrosis Risk Into Context<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Useful testing connects the reason for concern with the next decision. Explore the linked blood tests, discuss whether your existing results are sufficient, and make a plan for secondary assessment when needed. For broader liver-test interpretation, use the <a href=\"https:\/\/www.ultalabtests.com\/blog\/liver\/liver-function-tests\/\">Liver Function Tests guide<\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">References<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10735173\/\">AASLD Practice Guidance on the clinical assessment and management of NAFLD (2023)<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/news.gastro.org\/issues\/2026\/march\/aga-updates-masld-care-pathway\/\">AGA updates MASLD care pathway (2026 summary)<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.aasld.org\/new-masld-nomenclature\">AASLD: New MASLD nomenclature<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.niddk.nih.gov\/health-information\/liver-disease\/nafld-nash\/diagnosis\">NIDDK: Diagnosis of NAFLD and NASH<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease\">FDA: First treatment for liver scarring due to fatty liver disease<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash\">FDA: Wegovy treatment for MASH<\/a><\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Originally published:<\/strong> August 6, 2026 | <strong>Updated:<\/strong> September 17, 2026<\/p>\n","protected":false},"excerpt":{"rendered":"<p>How AST, ALT, platelets, A1C, lipids, and secondary fibrosis tests work together to guide evaluation and follow-up. MASLD fibrosis risk can be present even when liver enzymes fall within the laboratory reference interval. Metabolic dysfunction-associated [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":3185,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":true,"om_disable_all_campaigns":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[218,209,223,229,240,5951,169,5849,5956,86],"tags":[2035,2036,2136,2416,1859,2408,5232,2026,1843,2414,3485,1972,557,5230,1839,676,5360,3472,2129,5228,1978,5229,1850,494,5231,490,620],"class_list":["post-3169","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cirrhosis","category-liver","category-all-liver","category-liver-disease","category-liver-health","category-masld","category-metabolic","category-metabolic-health","category-metabolic-risk","category-metabolic-syndrome","tag-alt","tag-ast","tag-cardiometabolic-health","tag-elevated-liver-enzymes","tag-elf-test","tag-fatty-liver-disease","tag-fatty-liver-fibrosis-test","tag-ferritin","tag-fib-4-2","tag-fib-4-score-2","tag-fibroscan","tag-high-triglycerides","tag-insulin-resistance","tag-liver-elastography","tag-liver-fibrosis","tag-liver-function-tests","tag-liver-test-interpretation","tag-mash","tag-masld","tag-masld-fibrosis-risk","tag-metabolic-syndrome","tag-metald","tag-nafld","tag-obesity","tag-platelet-count","tag-prediabetes","tag-type-2-diabetes"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.3 (Yoast SEO v28.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>MASLD Fibrosis Risk: Testing for Silent Liver Scarring | Ulta Lab Tests<\/title>\n<meta name=\"description\" content=\"Understand MASLD fibrosis risk, the ELF test and liver scarring, plus why normal liver enzymes do not rule out a need for further assessment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ultalabtests.com\/blog\/liver\/masld-fibrosis-risk-before-symptoms\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MASLD Fibrosis Risk: Testing for Silent Liver Scarring\" \/>\n<meta property=\"og:description\" content=\"Understand MASLD fibrosis risk, the ELF test and liver scarring, plus why normal liver enzymes do not rule out a need for further assessment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ultalabtests.com\/blog\/liver\/masld-fibrosis-risk-before-symptoms\/\" \/>\n<meta property=\"og:site_name\" content=\"Ulta Lab Tests\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/facebook.com\/ultalabtests\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-18T21:40:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-20T22:55:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-fibrosis-risk-fib4-square.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"John R\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"John R\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"14 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MASLD Fibrosis Risk: Testing for Silent Liver Scarring | Ulta Lab Tests","description":"Understand MASLD fibrosis risk, the ELF test and liver scarring, plus why normal liver enzymes do not rule out a need for further assessment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ultalabtests.com\/blog\/liver\/masld-fibrosis-risk-before-symptoms\/","og_locale":"en_US","og_type":"article","og_title":"MASLD Fibrosis Risk: Testing for Silent Liver Scarring","og_description":"Understand MASLD fibrosis risk, the ELF test and liver scarring, plus why normal liver enzymes do not rule out a need for further assessment.","og_url":"https:\/\/www.ultalabtests.com\/blog\/liver\/masld-fibrosis-risk-before-symptoms\/","og_site_name":"Ulta Lab Tests","article_publisher":"https:\/\/facebook.com\/ultalabtests","article_published_time":"2026-09-18T21:40:14+00:00","article_modified_time":"2026-09-20T22:55:32+00:00","og_image":[{"width":1200,"height":1200,"url":"https:\/\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-fibrosis-risk-fib4-square.webp","type":"image\/webp"}],"author":"John R","twitter_card":"summary_large_image","twitter_misc":{"Written by":"John R","Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ultalabtests.com\/blog\/liver\/masld-fibrosis-risk-before-symptoms\/#article","isPartOf":{"@id":"https:\/\/www.ultalabtests.com\/blog\/liver\/masld-fibrosis-risk-before-symptoms\/"},"author":{"name":"John R","@id":"https:\/\/www.ultalabtests.com\/blog\/#\/schema\/person\/e9af1f4fe34b68909911dc95c313ed6a"},"headline":"MASLD Fibrosis Risk: Testing for Silent Liver Scarring","datePublished":"2026-09-18T21:40:14+00:00","dateModified":"2026-09-20T22:55:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ultalabtests.com\/blog\/liver\/masld-fibrosis-risk-before-symptoms\/"},"wordCount":2649,"commentCount":0,"publisher":{"@id":"https:\/\/www.ultalabtests.com\/blog\/#organization"},"image":{"@id":"https:\/\/www.ultalabtests.com\/blog\/liver\/masld-fibrosis-risk-before-symptoms\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-fibrosis-risk-fib4-square.webp?fit=1200%2C1200&quality=100&ssl=1","keywords":["ALT","AST","cardiometabolic health","Elevated Liver Enzymes","ELF test","Fatty Liver Disease","fatty liver fibrosis test","Ferritin","FIB-4","FIB-4 Score","FibroScan","high triglycerides","Insulin Resistance","liver elastography","liver fibrosis","Liver Function Tests","liver test interpretation","MASH","MASLD","MASLD fibrosis risk","metabolic syndrome","MetALD","NAFLD","obesity","platelet count","prediabetes","Type 2 Diabetes"],"articleSection":["Cirrhosis","Liver","Liver","Liver Disease","Liver Health","MASLD","Metabolic","Metabolic Health","Metabolic Risk","Metabolic Syndrome"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.ultalabtests.com\/blog\/liver\/masld-fibrosis-risk-before-symptoms\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.ultalabtests.com\/blog\/liver\/masld-fibrosis-risk-before-symptoms\/","url":"https:\/\/www.ultalabtests.com\/blog\/liver\/masld-fibrosis-risk-before-symptoms\/","name":"MASLD Fibrosis Risk: Testing for Silent Liver Scarring | Ulta Lab Tests","isPartOf":{"@id":"https:\/\/www.ultalabtests.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ultalabtests.com\/blog\/liver\/masld-fibrosis-risk-before-symptoms\/#primaryimage"},"image":{"@id":"https:\/\/www.ultalabtests.com\/blog\/liver\/masld-fibrosis-risk-before-symptoms\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-fibrosis-risk-fib4-square.webp?fit=1200%2C1200&quality=100&ssl=1","datePublished":"2026-09-18T21:40:14+00:00","dateModified":"2026-09-20T22:55:32+00:00","description":"Understand MASLD fibrosis risk, the ELF test and liver scarring, plus why normal liver enzymes do not rule out a need for further assessment.","breadcrumb":{"@id":"https:\/\/www.ultalabtests.com\/blog\/liver\/masld-fibrosis-risk-before-symptoms\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ultalabtests.com\/blog\/liver\/masld-fibrosis-risk-before-symptoms\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ultalabtests.com\/blog\/liver\/masld-fibrosis-risk-before-symptoms\/#primaryimage","url":"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-fibrosis-risk-fib4-square.webp?fit=1200%2C1200&quality=100&ssl=1","contentUrl":"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-fibrosis-risk-fib4-square.webp?fit=1200%2C1200&quality=100&ssl=1","width":1200,"height":1200,"caption":"FIB-4 combines age, AST, ALT, and platelet count to estimate the probability of advanced liver fibrosis."},{"@type":"BreadcrumbList","@id":"https:\/\/www.ultalabtests.com\/blog\/liver\/masld-fibrosis-risk-before-symptoms\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Ulta Lab Tests","item":"https:\/\/www.ultalabtests.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Liver","item":"https:\/\/www.ultalabtests.com\/blog\/category\/liver\/"},{"@type":"ListItem","position":3,"name":"MASLD Fibrosis Risk: Testing for Silent Liver Scarring"}]},{"@type":"WebSite","@id":"https:\/\/www.ultalabtests.com\/blog\/#website","url":"https:\/\/www.ultalabtests.com\/blog\/","name":"Ulta Lab Tests","description":"You Order the Test. We&#039;ll Do the Rest!","publisher":{"@id":"https:\/\/www.ultalabtests.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ultalabtests.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ultalabtests.com\/blog\/#organization","name":"Ulta Lab Tests","url":"https:\/\/www.ultalabtests.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ultalabtests.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2023\/02\/logo.png?fit=405%2C79&ssl=1","contentUrl":"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2023\/02\/logo.png?fit=405%2C79&ssl=1","width":405,"height":79,"caption":"Ulta Lab Tests"},"image":{"@id":"https:\/\/www.ultalabtests.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/facebook.com\/ultalabtests","http:\/\/www.linkedin.com\/company\/3335617"]},{"@type":"Person","@id":"https:\/\/www.ultalabtests.com\/blog\/#\/schema\/person\/e9af1f4fe34b68909911dc95c313ed6a","name":"John R","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/d48f9c8356694121fd9e2793e13d6aa6855e5df11f9b14f7a872b4ea554581fb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d48f9c8356694121fd9e2793e13d6aa6855e5df11f9b14f7a872b4ea554581fb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d48f9c8356694121fd9e2793e13d6aa6855e5df11f9b14f7a872b4ea554581fb?s=96&d=mm&r=g","caption":"John R"}}]}},"featured_image_src":"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-fibrosis-risk-fib4-square.webp?resize=600%2C400&quality=100&ssl=1","featured_image_src_square":"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-fibrosis-risk-fib4-square.webp?resize=600%2C600&quality=100&ssl=1","author_info":{"display_name":"John R","author_link":"https:\/\/www.ultalabtests.com\/blog\/author\/johnroehmultalabtests-com\/"},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/masld-fibrosis-risk-fib4-square.webp?fit=1200%2C1200&quality=100&ssl=1","_links":{"self":[{"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/posts\/3169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/comments?post=3169"}],"version-history":[{"count":0,"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/posts\/3169\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/media\/3185"}],"wp:attachment":[{"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/media?parent=3169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/categories?post=3169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/tags?post=3169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}